BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism
Top Cited Papers
Open Access
- 1 July 2007
- journal article
- other
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 92 (7), 2840-2843
- https://doi.org/10.1210/jc.2006-2707
Abstract
Context: BRAF mutations are common in papillary thyroid carcinomas (PTCs). By affecting the expression of genes critically related to the development and differentiation of thyroid cancer, they may influence the prognosis of these tumors. Objective: Our objective was to characterize the expression of thyroid-specific genes associated with BRAF mutation in PTCs. Design/Setting and Patients: We examined the expression of key markers of thyrocyte differentiation in 56 PTCs with BRAF mutations (BRAF-mut) and 37 with wild-type BRAF (BRAF-wt). Eight samples of normal thyroid tissue were analyzed as controls. Quantitative PCR was used to measure mRNA levels for the sodium/iodide symporter (NIS), apical iodide transporter (AIT-B), thyroglobulin (Tg), thyroperoxidase (TPO), TSH receptor (TSH-R), the transcription factor PAX8, and glucose transporter type 1 (Glut1). NIS protein expression and localization was also analyzed by immunohistochemistry. Results: mRNA levels for all thyroid-specific genes were reduced in all PTCs vs. normal thyroid tissues. NIS, AIT-B, Tg, and TPO expression was significantly lower in BRAF-mut tumors than in the BRAF-wt group. Glut-1 transcript levels were increased in all PTCs, and additional increases were noted in BRAF-mut tumors. In both tumor subsets, the NIS protein that was expressed was abnormally retained in the cytoplasm. Conclusion: BRAF V600E mutation in PTCs is associated with reduced expression of key genes involved in iodine metabolism. This effect may alter the effectiveness of diagnostic and/or therapeutic use of radioiodine in BRAF-mut PTCs.Keywords
This publication has 18 references indexed in Scilit:
- Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patientsNature Clinical Practice Endocrinology & Metabolism, 2007
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyJournal of Clinical Endocrinology & Metabolism, 2006
- Correlation between B-RAFV600E mutation and clinico–pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literatureEndocrine-Related Cancer, 2006
- Expression of tpo mRNA in thyroid tumors: quantitiative PCR analysis and correlation with alterations of ret, Braf , ras and pax8 genesEndocrine-Related Cancer, 2006
- The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membraneEndocrine-Related Cancer, 2006
- Biochemical and molecular characterization of the novel BRAFV599Ins mutation detected in a classic papillary thyroid carcinomaOncogene, 2006
- Modulation of Thyroid-Specific Gene Expression in Normal and Nodular Human Thyroid Tissues from Adults: An in Vivo Effect of ThyrotropinJournal of Clinical Endocrinology & Metabolism, 2005
- BRAF mutation in thyroid cancerEndocrine-Related Cancer, 2005
- Silencing of the Tumor Suppressor GeneSLC5A8Is Associated withBRAFMutations in Classical Papillary Thyroid CarcinomasJournal of Clinical Endocrinology & Metabolism, 2005
- BRAFV599EMutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid CarcinomasJournal of Clinical Endocrinology & Metabolism, 2004